Volume Alert - MRK 59.08 Merck & Company $MRK Hit a high today of 59.25 Closing the day 10:30 at 59.08 -0.56 -0.94% With a day low of 58.86 and a total volume of 1,381,366.
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
TechNavio Names Pfizer, Merck, F. Hoffmann-La Roche as Top Companies in the Global Human Growth Hormone Market
Business Wire - 3 mins ago
TechNavio, an independent tech-focused research firm, has published a list of the top 13 vendors in the Global Human Growth Hormone (HGH) Market, which is growing at a CAGR of 4.22 percent from 2015-2019.
PFE: 30.41 (-0.03), MRK: 59.30 (-0.34)
Sanofi's Bullish Pipeline Forecast Underwhelms Street
at Investor's Business Daily - 1 hr 34 mins ago
French big pharma Sanofi laid out its seven-year plan for drug launches, which it says will bring in a cumulative 30 billion euros ($37.6 billion) in their first five years of sales. But Sanofi stock slipped 3% in early trading on the stock market...
NVO: 44.33 (-0.41), MRK: 59.30 (-0.34), LLY: 66.90 (-0.31), SNY: 47.05 (-1.04), REGN: 413.25 (-2.00)
OsteoQC Closes Seed Financing Round
CNW Group - Thu Nov 20, 4:00AM CST
OsteoQC a company devoted to developing therapies for the treatment of bone-related diseases today announced the closing of a seed financing round. Lumira Capital Investment Management via its Merck Lumira Biosciences Fund led the financing, which represents part of Lumira's ongoing strategy to build early stage highly innovative health care technology companies with significant growth potential in Quebec.
MRK: 59.30 (-0.34)
Medical Breakthroughs On The Horizon For Merck
Vuru - at Seeking Alpha - Thu Nov 20, 2:08AM CST
Merck & Co. Inc. (NYSE: MRK ) Merck is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products. The company has a strong product presence in the cardiovascular,...
MRK: 59.30 (-0.34)
Lilly Shares Climb Despite Sales, Revenue Declines
Stock Traders Daily - at Seeking Alpha - Wed Nov 19, 11:50PM CST
PFE: 30.41 (-0.03), MRK: 59.30 (-0.34), DIA: 177.12 (+0.19), LLY: 66.90 (-0.31)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 107.96 (-0.80), PFE: 30.41 (-0.03), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19)
Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:57PM CST
Gilead's (GILD) hepatitis C virus drug, Harvoni, gained EU approval for the treatment of adults suffering from chronic hepatitis C genotype 1 and 4 infection.
BIIB: 301.84 (-1.77), GILD: 101.89 (-0.45), MRK: 59.30 (-0.34), ABBV: 65.61 (+0.11)
Research and Markets: Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
Business Wire - Wed Nov 19, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/kfktnx/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering.
PLL: 94.56 (-0.25), MRK: 59.30 (-0.34)
Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
M2 - Wed Nov 19, 11:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5b5rm/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering. The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014 Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market. The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW). MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures. The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing. The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Single Use Bioreactor Market, By Technology 8 Single Use Bioreactor Market, By Molecule Type 9 Single Use Bioreactor Market, By Type Of Cell 10 Single Use Bioreactor Market, By End User 11 Single Use Bioreactor Market, By Geography 12 Competitive Landscape 13 Company Profiles - Applikon Biotechnology - Cellexus Limited - Cellution Biotech - GE Healthcare (Subsidiary Of General Electric Company) - Merck Kgaa - Pall Corporation - Parker Hannifin Corporation - Pbs Biotech, Inc. - Sartorius Ag - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/k5b5rm/single_use
GE: 26.92 (unch), PLL: 94.56 (-0.25), MRK: 59.30 (-0.34)
Ezetimibe/simvastatin used in a fixed-dose combination Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
CNW Group - Wed Nov 19, 10:15AM CST
Merck, known as MSD outside of Canada and the United States, announced on November 17, 2014, that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine ezetimibe/simvastatin in a fixed-dose combination - the fixed-dose combination of ezetimibe/simvastatin is not available in Canada; the individual components: simvastatin (ZOCOR®) and ezetimibe (EZETROL®) are available in Canada - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented on November 17 during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.30 (-0.34)
Global Human Microbiome Market Report: Disease, Application & Product Analysis 2014-2019 & 2023
M2 - Wed Nov 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc2wtl/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023 Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side effects and diminishing of human gut flora, due to excessive use of antibiotics, is likely to drive the growth of the human microbiome market. The application market is also expected to be a prominent segment owing to the use of microbiome as diagnostics and therapeutics. The evidence from intransigent research resulted the use of microbiomes as biomarkers and diagnosis of various diseases. The disease segment, on the other hand, will be the fastest-growing segment in the coming years. With the growing incidences and increasing awareness of lifestyle diseases this market is set to grow at a fast pace. The grey area while estimating the market size was the uncertainty factor that lies with the current regulatory scenario for various products. The insights were provided by the industry experts who later clarified as to which disease segment will witness product approvals by the regulatory authorities and will enter the market in the future. Scope of the Report - Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) - Application (Therapeutic, Diagnostic) - Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sc...microbiome
MRK: 59.30 (-0.34)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 260.21 (-5.83), QLTI: 3.94 (-0.05), VRX: 142.07 (-0.40), AGN: 210.50 (-2.09), SHPG: 211.57 (+3.99), AUXL: 33.13 (+0.10), ABBV: 65.61 (+0.11), SNY: 47.05 (-1.04), ABT: 43.52 (+0.09), ENDP: 69.64 (+0.63), AKRX: 37.95 (-0.23), PFE: 30.41 (-0.03), INCY: 71.56 (+0.26), SLXP: 103.43 (-0.20), MYL: 55.47 (-0.21), AMGN: 164.58 (+1.94), LLY: 66.90 (-0.31), GSK: 46.51 (+0.26), BMY: 58.62 (-0.19), ACHN: 13.39 (+0.48), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ICPT: 156.75 (+0.82), TEVA: 57.30 (+0.05), NVS: 95.40 (-0.33)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 260.21 (-5.83), QLTI: 3.94 (-0.05), VRX: 142.07 (-0.40), AGN: 210.50 (-2.09), SHPG: 211.57 (+3.99), AUXL: 33.13 (+0.10), ABBV: 65.61 (+0.11), SNY: 47.05 (-1.04), ABT: 43.52 (+0.09), ENDP: 69.64 (+0.63), AKRX: 37.95 (-0.23), PFE: 30.41 (-0.03), INCY: 71.56 (+0.26), SLXP: 103.43 (-0.20), MYL: 55.47 (-0.21), AMGN: 164.58 (+1.94), LLY: 66.90 (-0.31), GSK: 46.51 (+0.26), BMY: 58.62 (-0.19), ACHN: 13.39 (+0.48), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ICPT: 156.75 (+0.82), TEVA: 57.30 (+0.05), NVS: 95.40 (-0.33)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 107.96 (-0.80), GILD: 101.85 (-0.49), MRK: 59.30 (-0.34), AMGN: 164.58 (+1.94), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19), CELG: 107.64 (+0.66)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 28.72 (-2.05), MRK: 59.30 (-0.34), REGN: 413.25 (-2.00)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.30 (-0.34), GSK: 46.51 (+0.26), NVS: 95.40 (-0.33)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.33 (-0.41), PFE: 30.40 (-0.04), MRK: 59.30 (-0.34), LLY: 66.90 (-0.31), SNY: 47.05 (-1.04), MNKD: 6.25 (-0.09)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 210.50 (-2.09), MRK: 59.30 (-0.34), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 210.50 (-2.09), ACT: 260.21 (-5.83), VRX: 142.07 (-0.40), MRK: 59.30 (-0.34), VRX.TO: 160.52 (-1.18)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.30 (-0.34)
MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/
MRK Merck & Company Recent Headline News
TechNavio Names Pfizer, Merck, F. Hoffmann-La Roche as Top Companies in the Global Human Growth Hormone Market
Business Wire - 3 mins ago
TechNavio, an independent tech-focused research firm, has published a list of the top 13 vendors in the Global Human Growth Hormone (HGH) Market, which is growing at a CAGR of 4.22 percent from 2015-2019.
PFE: 30.41 (-0.03), MRK: 59.30 (-0.34)
Sanofi's Bullish Pipeline Forecast Underwhelms Street
at Investor's Business Daily - 1 hr 34 mins ago
French big pharma Sanofi laid out its seven-year plan for drug launches, which it says will bring in a cumulative 30 billion euros ($37.6 billion) in their first five years of sales. But Sanofi stock slipped 3% in early trading on the stock market...
NVO: 44.33 (-0.41), MRK: 59.30 (-0.34), LLY: 66.90 (-0.31), SNY: 47.05 (-1.04), REGN: 413.25 (-2.00)
OsteoQC Closes Seed Financing Round
CNW Group - Thu Nov 20, 4:00AM CST
OsteoQC a company devoted to developing therapies for the treatment of bone-related diseases today announced the closing of a seed financing round. Lumira Capital Investment Management via its Merck Lumira Biosciences Fund led the financing, which represents part of Lumira's ongoing strategy to build early stage highly innovative health care technology companies with significant growth potential in Quebec.
MRK: 59.30 (-0.34)
Medical Breakthroughs On The Horizon For Merck
Vuru - at Seeking Alpha - Thu Nov 20, 2:08AM CST
Merck & Co. Inc. (NYSE: MRK ) Merck is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products. The company has a strong product presence in the cardiovascular,...
MRK: 59.30 (-0.34)
Lilly Shares Climb Despite Sales, Revenue Declines
Stock Traders Daily - at Seeking Alpha - Wed Nov 19, 11:50PM CST
PFE: 30.41 (-0.03), MRK: 59.30 (-0.34), DIA: 177.12 (+0.19), LLY: 66.90 (-0.31)
Rheumatoid Arthritis Therapeutics Clinical Trials Market by Region, Companies, Trial Status, Phase H2 2014
PRWeb - Wed Nov 19, 7:33PM CST
The clinical trial report, "Rheumatoid Arthritis Global Clinical Trials Review, H2, 2014" provides data on the Rheumatoid Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rheumatoid Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rheumatoid Arthritis. Complete Report is Available @ http://www.reportsnreports.com/reports/317200...-2014.html .
JNJ: 107.96 (-0.80), PFE: 30.41 (-0.03), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19)
Gilead Gains on Harvoni's EU Approval for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 4:57PM CST
Gilead's (GILD) hepatitis C virus drug, Harvoni, gained EU approval for the treatment of adults suffering from chronic hepatitis C genotype 1 and 4 infection.
BIIB: 301.84 (-1.77), GILD: 101.89 (-0.45), MRK: 59.30 (-0.34), ABBV: 65.61 (+0.11)
Research and Markets: Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
Business Wire - Wed Nov 19, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/kfktnx/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering.
PLL: 94.56 (-0.25), MRK: 59.30 (-0.34)
Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
M2 - Wed Nov 19, 11:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5b5rm/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering. The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014 Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market. The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW). MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures. The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing. The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Single Use Bioreactor Market, By Technology 8 Single Use Bioreactor Market, By Molecule Type 9 Single Use Bioreactor Market, By Type Of Cell 10 Single Use Bioreactor Market, By End User 11 Single Use Bioreactor Market, By Geography 12 Competitive Landscape 13 Company Profiles - Applikon Biotechnology - Cellexus Limited - Cellution Biotech - GE Healthcare (Subsidiary Of General Electric Company) - Merck Kgaa - Pall Corporation - Parker Hannifin Corporation - Pbs Biotech, Inc. - Sartorius Ag - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/k5b5rm/single_use
GE: 26.92 (unch), PLL: 94.56 (-0.25), MRK: 59.30 (-0.34)
Ezetimibe/simvastatin used in a fixed-dose combination Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
CNW Group - Wed Nov 19, 10:15AM CST
Merck, known as MSD outside of Canada and the United States, announced on November 17, 2014, that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine ezetimibe/simvastatin in a fixed-dose combination - the fixed-dose combination of ezetimibe/simvastatin is not available in Canada; the individual components: simvastatin (ZOCOR®) and ezetimibe (EZETROL®) are available in Canada - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented on November 17 during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.30 (-0.34)
Global Human Microbiome Market Report: Disease, Application & Product Analysis 2014-2019 & 2023
M2 - Wed Nov 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc2wtl/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023 Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side effects and diminishing of human gut flora, due to excessive use of antibiotics, is likely to drive the growth of the human microbiome market. The application market is also expected to be a prominent segment owing to the use of microbiome as diagnostics and therapeutics. The evidence from intransigent research resulted the use of microbiomes as biomarkers and diagnosis of various diseases. The disease segment, on the other hand, will be the fastest-growing segment in the coming years. With the growing incidences and increasing awareness of lifestyle diseases this market is set to grow at a fast pace. The grey area while estimating the market size was the uncertainty factor that lies with the current regulatory scenario for various products. The insights were provided by the industry experts who later clarified as to which disease segment will witness product approvals by the regulatory authorities and will enter the market in the future. Scope of the Report - Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) - Application (Therapeutic, Diagnostic) - Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sc...microbiome
MRK: 59.30 (-0.34)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 260.21 (-5.83), QLTI: 3.94 (-0.05), VRX: 142.07 (-0.40), AGN: 210.50 (-2.09), SHPG: 211.57 (+3.99), AUXL: 33.13 (+0.10), ABBV: 65.61 (+0.11), SNY: 47.05 (-1.04), ABT: 43.52 (+0.09), ENDP: 69.64 (+0.63), AKRX: 37.95 (-0.23), PFE: 30.41 (-0.03), INCY: 71.56 (+0.26), SLXP: 103.43 (-0.20), MYL: 55.47 (-0.21), AMGN: 164.58 (+1.94), LLY: 66.90 (-0.31), GSK: 46.51 (+0.26), BMY: 58.62 (-0.19), ACHN: 13.39 (+0.48), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ICPT: 156.75 (+0.82), TEVA: 57.30 (+0.05), NVS: 95.40 (-0.33)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 260.21 (-5.83), QLTI: 3.94 (-0.05), VRX: 142.07 (-0.40), AGN: 210.50 (-2.09), SHPG: 211.57 (+3.99), AUXL: 33.13 (+0.10), ABBV: 65.61 (+0.11), SNY: 47.05 (-1.04), ABT: 43.52 (+0.09), ENDP: 69.64 (+0.63), AKRX: 37.95 (-0.23), PFE: 30.41 (-0.03), INCY: 71.56 (+0.26), SLXP: 103.43 (-0.20), MYL: 55.47 (-0.21), AMGN: 164.58 (+1.94), LLY: 66.90 (-0.31), GSK: 46.51 (+0.26), BMY: 58.62 (-0.19), ACHN: 13.39 (+0.48), MRK: 59.30 (-0.34), AZN: 74.36 (-1.02), ICPT: 156.75 (+0.82), TEVA: 57.30 (+0.05), NVS: 95.40 (-0.33)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 107.96 (-0.80), GILD: 101.85 (-0.49), MRK: 59.30 (-0.34), AMGN: 164.58 (+1.94), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19), CELG: 107.64 (+0.66)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 28.72 (-2.05), MRK: 59.30 (-0.34), REGN: 413.25 (-2.00)
Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.30 (-0.34), GSK: 46.51 (+0.26), NVS: 95.40 (-0.33)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.33 (-0.41), PFE: 30.40 (-0.04), MRK: 59.30 (-0.34), LLY: 66.90 (-0.31), SNY: 47.05 (-1.04), MNKD: 6.25 (-0.09)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 210.50 (-2.09), MRK: 59.30 (-0.34), ABBV: 65.61 (+0.11), BMY: 58.62 (-0.19)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 210.50 (-2.09), ACT: 260.21 (-5.83), VRX: 142.07 (-0.40), MRK: 59.30 (-0.34), VRX.TO: 160.52 (-1.18)
Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST
MRK: 59.30 (-0.34)
